NovaBay Pharmaceuticals Regains Compliance With NYSE American Continued Listing Standards

EMERYVILLE, Calif.—NovaBay Pharmaceuticals, Inc., a developer of eyecare, skin care and wound care products, announced that it has regained compliance with the NYSE American's continued listing standards. The NYSE American notified the company on April 18, 2024, and May 28, 2024 that it was not in compliance with the continued listing standards of the NYSE American Company Guide, requiring a listed company to have stockholders' equity of at least $6 million. In June of 2024, as reported in VMAIL, NovaBay announced that the NYSE American LLC had accepted the company's plan to regain compliance with NYSE American's continued listing standards.